Oxaliplatin Added to Standard of Care Therapy Increased Disease-Free Survival for Rectal Cancer

Share this content:
Standard combined modality treatment for locally advanced rectal cancer had less disease-free survival than a new CRO/ARO/AIO-04 regimen.
Standard combined modality treatment for locally advanced rectal cancer had less disease-free survival than a new CRO/ARO/AIO-04 regimen.

The standard combined modality treatment for locally advanced rectal cancer established by the German CAO/ARO/AIO-94 trial treatment regimen had less disease-free survival than a new CRO/ARO/AIO-04 regimen, according to an article published ahead of print in The Lancet Oncology.

The standard of care established in the CAO/ARO/AIO-94 trial was preoperative chemoradiotherapy with infusional fluorouracil, total mesorectal excision surgery, and postoperative chemotherapy with fluorouracil.

Researchers in the phase 3 multicenter, open-label randomized trial (CRO/ARO/AIO-04) compared the previously established regimen with an investigational regimen that included the addition of oxaliplatin to preoperative and postoperative chemotherapy.

Patients with rectal adenocarcinoma (stage cT3-4 or any node-positive disease) were randomly assigned to two groups: the standard treatment (n=623) or the investigational (n=623).

With a median follow-up of 50 months, disease-free survival at 3 years was 75.9% in the investigational arm and 71.2% in the control group.

RELATED: Effect of mFOLFOX6 after Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

In regard to safety, of the 445 patients who received adjvujant fluorouracil and leucovorin, and oxaliplatin, 158 (36%), had grade 3-4 toxic effects, as did 170 (36%) of 470 patients who received fluorouracil.

Late grade 3/4 adverse effects in patients who received the investigational treatment occurred in 25%, and 21% of patients in the control group.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs